Senti Biosciences, Inc.
For the period ended Sep 30, 2025. Filed Nov 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 13, 2025
SNTI$0.16-0.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| September 30, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| CURRENT ASSETS | ||
| Cash and cash equivalents | $12,243 | $48,277 |
| Accounts receivable | 147 | 159 |
| GeneFab receivable - related party | 1,597 | 1,646 |
| GeneFab prepaid expenses - related party | 2,067 | 6,639 |
| Prepaid expenses and other current assets | 2,104 | 2,240 |
| Total current assets | 18,158 | 58,961 |
| Restricted cash | 3,540 | 3,538 |
| Property and equipment, net | 18,691 | 21,289 |
| Operating lease right-of-use assets | 12,262 | 13,948 |
| Other non-current assets | 34 | 105 |
| TOTAL ASSETS | $52,685 | $97,841 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES | ||
| Accounts payable | $1,771 | $1,454 |
| Accrued expenses and other current liabilities | 5,103 | 6,385 |
| Operating lease liabilities, current | 5,153 | 4,647 |
| GeneFab sublease deferred income - related party | — | 660 |
| Total current liabilities | 12,027 | 13,146 |
| Operating lease liabilities, non-current | 24,968 | 28,891 |
| Other non-current liabilities | 7,569 | 5,049 |
| TOTAL LIABILITIES | 44,564 | 47,086 |
| Commitments and contingencies (Note 13) | ||
| Series A redeemable convertible preferred stock, $0.0001 par value; zero and 21,200 shares authorized as of September 30, 2025 and December 31, 2024, respectively; zero and 21,157 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively; aggregate liquidation preference of zero and $147,647 as of September 30, 2025 and December 31, 2024, respectively | — | 25,106 |
| STOCKHOLDERS’ EQUITY | ||
| Common stock, $0.0001 par value; 500,000,000 shares authorized as of both September 30, 2025 and December 31, 2024; 26,290,838 and 4,829,035 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | 3 | 1 |
| Additional paid-in capital | 352,223 | 322,782 |
| Accumulated deficit | (344,105) | (297,134) |
| TOTAL STOCKHOLDERS’ EQUITY | 8,121 | 25,649 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $52,685 | $97,841 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.